Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $22.0 million.

  • Praxis Precision Medicines' Shares Outstanding (Diluted Average) rose 16.38% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 16.38%. This contributed to the annual value of $17.9 million for FY2024, which is 171.55% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Shares Outstanding (Diluted Average) stood at $22.0 million, which was up 2.34% from $21.5 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Shares Outstanding (Diluted Average) high stood at $45.8 million for Q3 2022, and its period low was $3.1 million during Q4 2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $14.4 million, with a median of $17.9 million in 2024.
  • In the last 5 years, Praxis Precision Medicines' Shares Outstanding (Diluted Average) slumped by 92.21% in 2023 and then soared by 304.88% in 2024.
  • Quarterly analysis of 4 years shows Praxis Precision Medicines' Shares Outstanding (Diluted Average) stood at $3.1 million in 2022, then surged by 114.58% to $6.6 million in 2023, then soared by 171.55% to $17.9 million in 2024, then climbed by 16.38% to $22.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $22.0 million for Q3 2025, versus $21.5 million for Q2 2025 and $21.1 million for Q1 2025.